Xyall BV, a next-generation innovator in molecular pathology, has raised €7.6 million in new funding to accelerate the global rollout of its automated tissue dissection platform. The financing round was led by Capricorn Partners through its Capricorn Healthtech Fund II, with participation from Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and several private investors.
The proceeds will support the international expansion of Xyall’s Tissector TableTop, an automated tissue dissection system currently deployed in more than 15 molecular pathology laboratories. The installed base includes Tier 1 commercial, academic, pharmaceutical, and research institutions in the United States, reflecting growing demand for scalable, reliable automation in molecular diagnostics.
Tissue dissection remains largely manual and labor-intensive in many laboratories, relying on subjective assessment, and is vulnerable to error and cross-contamination. Xyall’s platform integrates high-resolution slide imaging, precise image registration, workflow optimization, and high-precision robotics to deliver a fully automated solution that improves efficiency and accuracy.
Introduced in 2023, the Tissector TableTop was designed to address practical operational challenges faced by molecular pathology labs. Its adoption by leading hospital laboratories underscores its clinical relevance and operational value, particularly as labs face mounting pressure to deliver faster, more precise diagnostic results amid a global shortage of specialized staff.
In current workflows, pathologists manually mark Regions of Interest on hematoxylin and eosin-stained slides. Laboratory technicians then visually transfer those markings onto dissection slides and manually scrape tissue for downstream molecular analysis. This process is time-consuming, difficult to scale, and increasingly strained by staffing shortages.
Xyall positions its automated tissue dissection technology as a bridge between morphological assessment and molecular diagnostics, enabling laboratories to streamline a critical step that has historically been manual despite rapid advances in PCR and next-generation sequencing.
KEY QUOTES
“Molecular diagnostics play a key role in determining the most appropriate treatment, particularly in oncology. Laboratories are under increasing pressure to deliver results faster and more accurately, while facing a global shortage of specialized staff. The fact that the Tissector Table Top is already deployed in more than fifteen high standing laboratories confirms that we are addressing a real and urgent need. Over the past decade, PCR and next-generation sequencing technologies have advanced rapidly. However, the critical step of selecting tumor tissue for molecular analysis has remained largely manual, subjective, and imprecise. With our fully automated tissue dissection solutions, Xyall provides the missing link between morphological and molecular diagnostics.”
Guido du Pree, CEO of Xyall
“Xyall enables pathology labs to operate more efficiently, and the evidence shows that it also supports more accurate diagnoses — particularly in fields like oncology where personalized treatment plans are essential. Xyall is at the beginning of a period of rapid growth across both research and clinical laboratories. This investment will help the company accelerate its development and establish itself as a global leader in this domain.”
Dick Sietses, Investment Partner at Capricorn Partners
“At BOM, we invest in companies that help address pressing societal challenges and strengthen the quality and accessibility of healthcare. Xyall’s technology has the potential to significantly improve the accuracy and efficiency of molecular pathology, supporting better diagnostics for patients worldwide. The company is showing impressive progress in commercial traction and technological capability, and we see significant global potential. With the addition of an experienced new investor, the consortium is even better positioned to support Xyall as they scale their impact in molecular pathology.”
Monique Dullens, Investment Manager at BOM
